Communiqués de presse Archive - Page 3 of 24 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics provides an update on ongoing proceedings

OSE Immunotherapeutics Publishes Letter to Shareholders

OSE Immunotherapeutics provides an update on ongoing proceedings

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

Adjournment of the General Meeting initially convened on June 25, 2025

Update on the terms of the Shareholders General Meeting

Documents made available to the shareholders for the combined general meeting of June 25th, 2025

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

Précédent
1
2
3
4
5
6
7
8
9
…
24
Suivant